Coronary DiseaseNCT04171570
DIStal Versus COnventional RADIAL Access for Coronary Angiography and Intervention
A study testing Coronary angiography and or Percutaneous coronary Intervention in people with Coronary Disease, run by Terumo Europe N.V. at 16 sites in 10 countries.
Trial summary
The objective of this study is to demonstrate the superiority of Distal Radial Access (DTRA) to Conventional Transradial Access (CTRA) regarding forearm radial artery occlusion (RAO). Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Coronary Disease
- What is being tested?
- Coronary angiography and or Percutaneous coronary Intervention
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 1,309 participants
- Where
- 16 sitesin 10 countries
- Study dates
- 10 Dec 2019to 28 Dec 2021
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Patient is at least 18 years of age.
- Patient has provided written informed consent.
- Patient is undergoing diagnostic coronary angiography and/or PCI.
- Patient is willing to comply with all protocol-required evaluations during the hospitalization.
- Patient is suitable for both DTRA and CTRA using 6Fr GSS.
Who cannot join
- Patient has a medical condition that may cause non-compliance with the protocol and/or confound the data interpretation.
- Patients on chronic hemodialysis.
- Patients presenting with ST-elevated myocardial infarction (STEMI).
- Patients have chronic total occlusion (CTO) lesions in coronary artery.
Trial locations and contacts
16 sites in 10 countries.
16 sites in 10 countries
Belgium4 sites
UZ Brussel
Brussels, 1090
Hôpital Civil Marie Curie
Charleroi, Hainaut, 6042
CHU Jolimont
Haine-Saint-Paul, Hainaut, 7100
Cliniques Universitaires Saint-Luc
Woluwe-Saint-Lambert, Brussels Capital, 1200
Italy2 sites
Sant'Eugenio Hospital
Roma, 00144
Istituto Clinico Humanitas
Rozzano, 20089
Switzerland2 sites
HUG Geneva
Geneva, 1211
Kantonsspital Baselland Liestal
Liestal, CH-4410
United Kingdom2 sites
Royal Stoke University Hospital
Stoke-on-Trent, ST4 6QG
Sunderland Royal Hospital
Sunderland
Germany1 site
University Hospital Johannes Wesling Klinikum Minden
Minden, 32429
North Macedonia1 site
University Clinic of Cardiology, Skopje
Skopje, 1000
About this study
Official title: DISCO Radial Trial: DIStal Versus COnventional RADIAL Access for Coronary Angiography and Intervention: a Randomized Multicenter Trial
The objective of this study is to demonstrate the superiority of Distal Radial Access (DTRA) to Conventional Transradial Access (CTRA) regarding forearm radial artery occlusion (RAO).
This trial plans to include 1300 patients in around 12 locations around the world (11 participating sites in Europe and 1 participating site in Japan).
Read the detailed description
DISCO RADIAL is a prospective, global, open label, multi-centre randomized controlled trial with plan to include approximately 1300 patients on who transradial coronary angiography and/or intervention is performed. The patients will be randomized in 1:1 ratio to either Distal Transradial Artery Access (DTRA) or Conventional Transradial Access (CTRA) arm. In both arms 6Fr Glidesheath Slender (GSS) will be used as access sheath.
The sponsor will work in accordance with standard operating procedures (SOP) and the Monitoring Plan in order to ensure adherence to the CIP and applicable regulations at the investigational sites.
The Monitoring Plan is built according to a risk-based monitoring approach and describes the level of source data verification to be performed by the monitors.
Risk-based monitoring approach uses all available means to supervise the trial (central monitoring, remote monitoring and on-site monitoring), focusing in critical data points and issues ensuring that adequate monitoring (central, remote and on-site) at each site is completed to ensure protection of the rights and safety of the subjects and the quality and integrity of the data collected and submitted.
The sponsor shall provide training and the necessary guidelines to assist each investigational site on the data collection in the eCRF. Each site is responsible to report the available data requested by the CIP. In order to ensure data quality and avoid missing information in the eCRF, edit checks are designed during database development. In addition, Sponsor's CRA and Data Management team will be responsible to review the data and raise queries accordingly into the eCRF. An audit trail logging all data entered and edited is available within the EDC system. All source documents are maintained in the hospital files ready for inspection by the Sponsor and regulatory authorities upon request. The Sponsor will inform the investigator of the time period for retaining these records as per applicable regulatory requirements.
The following analysis sets will be considered for the statistical analysis :
As Treated Population This population includes all patients who were treated and undergo the studied procedure. Patients will be assigned to the study treatement groups according to the actual received treatement.
Intention-To-Treat Population This population includes all patients who have been randomized to a treatement. Patients will be assigned to the study treatement groups according to the treatement to which they have been randomized.
Per-Protocol Population This population includes all patients who were treated and undergo the studied procedure, excluding all patients with major violations to the protocol (e.g. wrong inclusion, missing data, mis-randomization, crossover, drop off before discharge). Patients will be assigned to the study treatement groups according to the treatement to which they have been randomized. All the protocol deviations will be reported in statistical report.
Assuming a rate of forearm RAO of 1% in DTRA and 3.5% in CTRA based on on two-sided alpha = 0.050 and power = 80%, 1:1 randomization needs 551 patients for each group to detect statistically significant differences in forearm RAO proportions. Then, given the crossover rate of 10% and the drop out rate of 5% for both group, at least 648 patients needs for each group to maintain proper statistical power. In total 1300 subjects will be randomized.
The primary endpoint analysis will be performed on ITT (Intention-To-Treat) population, by using two-sided superiority test with alpha = 0.05. Due to the short observation period (3 days ±2), a low number of missing data is expected. However, in case it exceeds 15-20%, missing, unused or spurious data will be considered using a tipping point analysis for each population. The comparaison in RAO rates between treatment groups will be tested by Chi-squared tests or Fisher's exact test, as appropriate. Odd-Ratio with IC95% will be calculated. Logistic regression analyses will be used to test the tendency.
- Conditions
- Coronary Disease
- Being tested
- Coronary angiography and or Percutaneous coronary Intervention
- Keywords
- Distal Transradial Access, Randomized Multicenter Trial, Radial Access
- Medical subject headings
- Coronary Disease
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Coronary angiography and or Percutaneous coronary InterventionProcedure or surgery
Radial access punture site
| Study group | Role | What they receive |
|---|---|---|
| Distal Transradial Access | Other | Distal Transradial Access Receives: Procedure: Coronary angiography and or Percutaneous coronary Intervention |
| Conventional Transradial Access | Other | Conventional Transradial Access Receives: Procedure: Coronary angiography and or Percutaneous coronary Intervention |
What is being measured
The primary outcome is the main question the study is designed to answer.
Forearm radial artery occlusion (RAO) rate before discharge
Forearm radial artery occlusion (RAO) rate before discharge measured with Doopler Ultrasound
Measured: up to 5 days
Secondary outcomes (12)
Rate of successful sheath insertion
Rate of successful sheath insertion obtained though eCRF question
Measured: up to 2 days
Rate of access site crossover
Rate of access site crossover - if the initial access point fails physician can perform the procedure using other access site of his/her choice This data point is captured on the eCRF
Measured: up to 2 days
Total procedural time
Total procedural time defined as the time between initiation of local anesthesia to sheath removal - information captured on the eCRF
Measured: up to 2 days
Sheath insertion time
Sheath insertion time recorded in the eCRF and defined as when puncture with the introducer needle first attempted until the time when introducer sheath is successfully inserted
Measured: up to 2 days
Puncture site bleeding according to EASY criteria
Puncture site bleeding according to EASY criteria
Measured: up to 5 days
Overall bleeding according to BARC criteria
Overall bleeding according to BARC criteria
Measured: up to 5 days
Vascular access-site complication
Vascular access-site complication documented on the eCRF. It is composed by the rate of vessel perforation after occlusion requiring intervention, arterial dissection, pseudoaneurysm, and local haematoma
Measured: up to 5 days
Rate of radial artery spasm
Rate of radial artery spasm captured in the eCRF. Radial arety spasm is defined as an inability to manipulate the guidewire or catheter in a smooth and pain-free manner and also as an inability to remove the sheath in a similar way at the end of the procedure
Measured: up to 2 days
Rate of distal radial artery occlusion (dRAO)
Rate of distal radial artery occlusion (dRAO) by doopler ultrasound and capture in the eCRF
Measured: up to 5 days
Patent hemostasis was achieved or not (CTRA) by reverse barbeau test
Patent hemostasis was achieved or not (CTRA) by reverse barbeau test
Measured: up to 5 days
Time required to reach hemostasis
Time required to reach hemostasis, captured on the eCRF and defined as the time between sheath removal to complete hemostasis
Measured: up to 5 days
Pain associated with the procedure: Visual Assessment Scale (VAS)
Pain associated with the procedure measured by the Visual Assessment Scale (VAS), a numeric rating scale. VAS is a 10 cm line with anchor statements on the left (no pain = 0) and on the right (worst possible pain = 10)
Measured: up to 5 days
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted21 Nov 2019
- Study start10 Dec 2019
- Primary completion28 Dec 2021
- Study completion28 Dec 2021
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (4)Papers the sponsor has linked to this study.
- Other trials for Coronary DiseaseStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Randomization to distal transradial access or conventional transradial access. Both techniques are standard of care.
- Masking
- None (open label)
- Enrolment
- 1,309 participants (actual)
Sponsor and investigators
- Lead sponsor
- Terumo Europe N.V.
- Sponsor type
- Industry (pharma, biotech, devices)
- Collaborators
- Cromsource
- Responsible party
- Sponsor
- Investigators
- Adel Aminian, Dr., Principal investigator, Hôpital Civil Marie Curie
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04171570
- Sponsor's protocol ID
- T133E3
- Status last verified
- May 2022
- First submitted
- 23 Oct 2019
- Last updated
- 24 May 2022
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Kiemeneij F. Left distal transradial access in the anatomical snuffbox for coronary angiography (ldTRA) and interventions (ldTRI). EuroIntervention. 2017 Sep 20;13(7):851-857. doi: 10.4244/EIJ-D-17-00079.
PubMed 28506941Corcos T. Distal radial access for coronary angiography and percutaneous coronary intervention: A state-of-the-art review. Catheter Cardiovasc Interv. 2019 Mar 1;93(4):639-644. doi: 10.1002/ccd.28016. Epub 2018 Dec 11.
PubMed 30536709Sgueglia GA, Di Giorgio A, Gaspardone A, Babunashvili A. Anatomic Basis and Physiological Rationale of Distal Radial Artery Access for Percutaneous Coronary and Endovascular Procedures. JACC Cardiovasc Interv. 2018 Oct 22;11(20):2113-2119. doi: 10.1016/j.jcin.2018.04.045.
PubMed 30336816Aminian A, Saito S, Takahashi A, Bernat I, Jobe RL, Kajiya T, Gilchrist IC, Louvard Y, Kiemeneij F, Van Royen N, Yamazaki S, Matsukage T, Rao SV. Comparison of a new slender 6 Fr sheath with a standard 5 Fr sheath for transradial coronary angiography and intervention: RAP and BEAT (Radial Artery Patency and Bleeding, Efficacy, Adverse evenT), a randomised multicentre trial. EuroIntervention. 2017 Aug 4;13(5):e549-e556. doi: 10.4244/EIJ-D-16-00816.
PubMed 28218605
Study at a glance
From the registry record, last updated by the sponsor on 24 May 2022. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- DISCO Radial Trial: DIStal Versus COnventional RADIAL Access for Coronary Angiography and Intervention: a Randomized Multicenter Trial
- ClinicalTrials.gov ID
- NCT04171570
- Acronym / sponsor ID
- T133E3
- Conditions
- Coronary Disease
- Keywords
- Distal Transradial Access, Randomized Multicenter Trial, Radial Access
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 1,309 participants (actual)
- Lead sponsor
- Terumo Europe N.V.Industry (pharma, biotech, devices)
- Collaborators
- Cromsource
- Study start
- 10 Dec 2019 (actual)
- Primary completion
- 28 Dec 2021 (actual)
- Study completion
- 28 Dec 2021 (actual)
- First posted
- 21 Nov 2019 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The objective of this study is to demonstrate the superiority of Distal Radial Access (DTRA) to Conventional Transradial Access (CTRA) regarding forearm radial artery occlusion (RAO).
This trial plans to include 1300 patients in around 12 locations around the world (11 participating sites in Europe and 1 participating site in Japan).
Detailed description
DISCO RADIAL is a prospective, global, open label, multi-centre randomized controlled trial with plan to include approximately 1300 patients on who transradial coronary angiography and/or intervention is performed. The patients will be randomized in 1:1 ratio to either Distal Transradial Artery Access (DTRA) or Conventional Transradial Access (CTRA) arm. In both arms 6Fr Glidesheath Slender (GSS) will be used as access sheath.
The sponsor will work in accordance with standard operating procedures (SOP) and the Monitoring Plan in order to ensure adherence to the CIP and applicable regulations at the investigational sites.
The Monitoring Plan is built according to a risk-based monitoring approach and describes the level of source data verification to be performed by the monitors.
Risk-based monitoring approach uses all available means to supervise the trial (central monitoring, remote monitoring and on-site monitoring), focusing in critical data points and issues ensuring that adequate monitoring (central, remote and on-site) at each site is completed to ensure protection of the rights and safety of the subjects and the quality and integrity of the data collected and submitted.
The sponsor shall provide training and the necessary guidelines to assist each investigational site on the data collection in the eCRF. Each site is responsible to report the available data requested by the CIP. In order to ensure data quality and avoid missing information in the eCRF, edit checks are designed during database development. In addition, Sponsor's CRA and Data Management team will be responsible to review the data and raise queries accordingly into the eCRF. An audit trail logging all data entered and edited is available within the EDC system. All source documents are maintained in the hospital files ready for inspection by the Sponsor and regulatory authorities upon request. The Sponsor will inform the investigator of the time period for retaining these records as per applicable regulatory requirements.
The following analysis sets will be considered for the statistical analysis :
As Treated Population This population includes all patients who were treated and undergo the studied procedure. Patients will be assigned to the study treatement groups according to the actual received treatement.
Intention-To-Treat Population This population includes all patients who have been randomized to a treatement. Patients will be assigned to the study treatement groups according to the treatement to which they have been randomized.
Per-Protocol Population This population includes all patients who were treated and undergo the studied procedure, excluding all patients with major violations to the protocol (e.g. wrong inclusion, missing data, mis-randomization, crossover, drop off before discharge). Patients will be assigned to the study treatement groups according to the treatement to which they have been randomized. All the protocol deviations will be reported in statistical report.
Assuming a rate of forearm RAO of 1% in DTRA and 3.5% in CTRA based on on two-sided alpha = 0.050 and power = 80%, 1:1 randomization needs 551 patients for each group to detect statistically significant differences in forearm RAO proportions. Then, given the crossover rate of 10% and the drop out rate of 5% for both group, at least 648 patients needs for each group to maintain proper statistical power. In total 1300 subjects will be randomized.
The primary endpoint analysis will be performed on ITT (Intention-To-Treat) population, by using two-sided superiority test with alpha = 0.05. Due to the short observation period (3 days ±2), a low number of missing data is expected. However, in case it exceeds 15-20%, missing, unused or spurious data will be considered using a tipping point analysis for each population. The comparaison in RAO rates between treatment groups will be tested by Chi-squared tests or Fisher's exact test, as appropriate. Odd-Ratio with IC95% will be calculated. Logistic regression analyses will be used to test the tendency.
Study design
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
- Model description
- Randomization to distal transradial access or conventional transradial access. Both techniques are standard of care.
| Arm | Type | Receives |
|---|---|---|
| Distal Transradial Access | Other | Procedure: Coronary angiography and or Percutaneous coronary InterventionDistal Transradial Access |
| Conventional Transradial Access | Other | Procedure: Coronary angiography and or Percutaneous coronary InterventionConventional Transradial Access |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- Patient is at least 18 years of age.
- Patient has provided written informed consent.
- Patient is undergoing diagnostic coronary angiography and/or PCI.
- Patient is willing to comply with all protocol-required evaluations during the hospitalization.
- Patient is suitable for both DTRA and CTRA using 6Fr GSS.
Key exclusion criteria (4 listed)
- Patient has a medical condition that may cause non-compliance with the protocol and/or confound the data interpretation.
- Patients on chronic hemodialysis.
- Patients presenting with ST-elevated myocardial infarction (STEMI).
- Patients have chronic total occlusion (CTO) lesions in coronary artery.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Coronary angiography and or Percutaneous coronary InterventionRadial access punture site | Procedure or surgery | Conventional Transradial Access, Distal Transradial Access |
Primary outcome
Forearm radial artery occlusion (RAO) rate before discharge
Time frame: up to 5 days
Forearm radial artery occlusion (RAO) rate before discharge measured with Doopler Ultrasound
12 secondary outcomes
Rate of successful sheath insertion
Time frame: up to 2 days
Rate of access site crossover
Time frame: up to 2 days
Total procedural time
Time frame: up to 2 days
Sheath insertion time
Time frame: up to 2 days
Puncture site bleeding according to EASY criteria
Time frame: up to 5 days
Overall bleeding according to BARC criteria
Time frame: up to 5 days
Vascular access-site complication
Time frame: up to 5 days
Rate of radial artery spasm
Time frame: up to 2 days
Rate of distal radial artery occlusion (dRAO)
Time frame: up to 5 days
Patent hemostasis was achieved or not (CTRA) by reverse barbeau test
Time frame: up to 5 days
Time required to reach hemostasis
Time frame: up to 5 days
Pain associated with the procedure: Visual Assessment Scale (VAS)
Time frame: up to 5 days
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 24 May 2022.
- Background: PubMed 28506941Kiemeneij F. Left distal transradial access in the anatomical snuffbox for coronary angiography (ldTRA) and interventions (ldTRI). EuroIntervention. 2017 Sep 20;13(7):851-857. doi: 10.4244/EIJ-D-17-00079.
- Background: PubMed 30536709Corcos T. Distal radial access for coronary angiography and percutaneous coronary intervention: A state-of-the-art review. Catheter Cardiovasc Interv. 2019 Mar 1;93(4):639-644. doi: 10.1002/ccd.28016. Epub 2018 Dec 11.
- Background: PubMed 30336816Sgueglia GA, Di Giorgio A, Gaspardone A, Babunashvili A. Anatomic Basis and Physiological Rationale of Distal Radial Artery Access for Percutaneous Coronary and Endovascular Procedures. JACC Cardiovasc Interv. 2018 Oct 22;11(20):2113-2119. doi: 10.1016/j.jcin.2018.04.045.
- Background: PubMed 28218605Aminian A, Saito S, Takahashi A, Bernat I, Jobe RL, Kajiya T, Gilchrist IC, Louvard Y, Kiemeneij F, Van Royen N, Yamazaki S, Matsukage T, Rao SV. Comparison of a new slender 6 Fr sheath with a standard 5 Fr sheath for transradial coronary angiography and intervention: RAP and BEAT (Radial Artery Patency and Bleeding, Efficacy, Adverse evenT), a randomised multicentre trial. EuroIntervention. 2017 Aug 4;13(5):e549-e556. doi: 10.4244/EIJ-D-16-00816.
- Individual participant dataSharing planned: No
Related trials for Coronary Disease
Not yet recruiting
Effect of Stress Ball Use During Femoral Arterial Sheath Removal After Coronary Angiography
Femoral Arterial Sheath Removal, Stress Ball
Active, not recruiting
Shockwave™ vs Surgical Endarterectomy for Calcified Severe Common Femoral Artery Stenosis: Comparison of Efficacy, Safety and Long-Term Outcomes
Common Femoral Artery Stenosis, Calcification; Heart
RecruitingObservational study
AI-powered ECG Analysis Using Willem™ Software in High-risk Cardiac Patients (WILLEM)
Cardiomyopathies, Cardiac Arrest
RecruitingPhase 4
The Effects of Ferric Derisomaltose in Patients With Acute Heart Failure and Iron Deficiency on Exercise Capacity and Quality of Life(COREVIVE-HFrEF)
Heart Failure With Reduced Ejection Fraction, Iron Deficiency
Recruiting
Trial of the F2 Filter and Delivery System for Embolic Protection During TAVR
Aortic Stenosis Treated With TAVI, Aortic Diseases
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Adel Aminian, Dr. principal investigator
Hôpital Civil Marie Curie
16 sites in 10 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Coronary angiography and or Percutaneous coronary Intervention in people with Coronary Disease, run by Terumo Europe N.V. at 16 sites in 10 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 24 May 2022. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 16 sites in Belgium, Italy, Switzerland, United Kingdom, Czechia and 5 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Forearm radial artery occlusion (RAO) rate before discharge (time frame: up to 5 days). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT04171570, which also lists 4 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 May 2022.